BioBlast Announces the Start of a Phase 3 Study for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioBlast Announces the Start of a Phase 3 Study for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)

TEL AVIV, Israel, June 15, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq: ORPN ), a clinical-stage orphan disease-focused biotechnology company, announced today the start of a Phase 3 pivotal study in the USA and Canada for Cabaletta (trehalose) in Oculopharyngeal Muscular Dystrophy (OPMD).

Colin Foster, BioBlast's President and CEO said, "We see positive signals in a consequential number of the 25 treated patients currently enrolled in our open label HOPEMD study, with respect to various muscle and other performance tests. These positive signals lead us to believe that the clinical study duration required to demonstrate efficacy may be considerably shorter than we initially predicted.

"Based upon various in vivo and cellular models of disease, we had initially expected to slow the deterioration of the disease over a period of 18 months in the HOPEMD study. Instead, we have seen evidence of improvement in a number of the functional measures within approximately the first six months. 

"While we had expected that we would see a reduction in the rate of decline for these patients, we were very pleased to note in several muscle group strength tests, functional muscle tests, and the drinking test as well as several patient reported outcome measures, there were significant improvements over baseline levels. These are interim results and a randomized open label study should be cautiously interpreted. Nevertheless we are encouraged by these findings and hope to see that this positive signal continues as the study progresses.

"As a result, we have made the decision to initiate a 12 month, placebo-controlled, multi-center Phase 3 study in the next quarter that will begin enrolling approximately 60 OPMD patients in the USA and Canada into this new trial.  We have stopped enrollment in the HOPEMD trial at twenty-five patients -- we had originally intended to enroll 70 patients. New OPMD patients will now be enrolled in the Phase 3 pivotal study. We anticipate that this Phase 3 study will be completed by the end of 2016, and because of its shorter duration, will provide results at the same time as the HOPEMD study. 

"Consequently, we believe this new Phase 3 study will expedite our OPMD program towards a regulatory filing."

About Oculopharyngeal Muscular Dystrophy (OPMD)

OPMD is a rare inherited myopathy characterized by dysphagia (difficulty in swallowing), the loss of muscle strength and weakness in multiple parts of the body. Patients typically suffer from severe dysphagia, ptosis (eye lid drooping), tongue atrophy, proximal lower limb weakness, dysphonia (altered and weak voice), limitation in looking upward, facial muscle weakness and proximal upper limb weakness. The disease is most often diagnosed in the fifth-sixth decade of life and progresses throughout the patient's life. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last two are often the cause of death.

There is no medical treatment or, to our knowledge, potential cure for OPMD. Current therapeutic strategies are confined to surgical interventions that have limited efficacy and need to be repeated.

About BioBlast

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.

The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. For more information please visit the Company's website, www.bioblast-pharma.com , the content of which is not incorporated herein by reference.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss that the required duration of our clinical trials necessary to demonstrate efficacy, the progress, design, timing, completion and announcing of results of our clinical trials, that certain clinical trials may lead to regulatory approval or that such trials may be considered pivotal, that our diverse portfolio of product candidates has the potential to address unmet medical needs for incurable genetic orphan diseases, or that our platforms potentially address unmet medical needs and offer solutions for several diseases that share the same biological pathology. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results would not be interpreted differently in light of additional research and clinical and preclinical trials results. Because such statements deal with future events and are based on BioBlast Pharma's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of BioBlast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading "Risk Factors" in BioBlast Pharma's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 31, 2015, and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

U.S. Investor Contact Andrew McDonald Founding Partner LifeSci Advisors, LLC 646-597-6987

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 147

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 124

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 71

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 250

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 58

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 126

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 62

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading

Top 5 Most Recently Viewed Articles

Eimskip's Q3 2025 Financial Overview and Future Outlook

Updated Category News Views 238

Eimskip's Third Quarter Performance Analysis The results for the third quarter of 2025 have presented challenges for Eimskip, as operations did not meet expectations. Revenues showed significant shifts, revealing both obstacles and opportunities in the company's journey. Operational Insights During Q3, Eimskip experienced a slight increase in liner shipping volumes,...

Continue Reading
Market Trends and Insights: The Bullish Moves on Block

Updated Category News Views 88

Examining Recent Bullish Moves on Block Recently, financial institutions have been making significant bullish strides into Block, a company known for its innovative payment services. Analysis of the options trading history for Block (NASDAQ: SQ) indicates a noticeable interest, with 16 unusual trades captured, providing insights into market direction and trader sentiment....

Continue Reading
Exploring the Soaring Online Poker Market Growth Trends

Updated Category News Views 157

Online Poker Market: A Surge on the Horizon The Global Online Poker Market is currently undergoing a transformative expansion, predicted to rise from USD 7.98 billion in 2024 to an impressive USD 37.19 billion by 2030. This notable growth reflects a compound annual growth rate (CAGR) of 29.24%, driven by advancements in technology such as enhanced smartphone capabilities,...

Continue Reading
Elevate Your Gaming with Jackbit's New Crypto Welcome Offer

Updated Category News Views 182

Jackbit’s New Welcome Bonus for Crypto Players As online gaming evolves, Jackbit Crypto Casino is launching an exciting new welcome bonus tailored specifically for cryptocurrency enthusiasts. Starting next year, all new players joining the Jackbit platform will enjoy the same welcome bonuses that traditional fiat customers have been taking advantage of. This bold move...

Continue Reading
Eli Lilly's Mounjaro Drug Set to Revolutionize Weight Loss in Hong Kong

Updated Category News Views 214

Eli Lilly to Launch Weight Loss Drug Mounjaro in Hong Kong Eli Lilly & Co. (NYSE: LLY) is poised to launch its well-regarded weight-loss medication, Mounjaro, in Hong Kong shortly. This marks an exciting milestone, as it positions Mounjaro to be the first of its kind available in the broader region of China. The anticipated launch follows recent reports indicating that...

Continue Reading